China Biotech Week in Review: China Encourages Private Entities to Invest in Healthcare

chinabiotodaynewlogo ChinaBio Today submits:

Bayer Healthcare [XETRA: BAY] has announced plans to expand its Beijing pharmaceutical R&D center, even though other big pharmas are scaling back their worldwide R&D operations (see story). In an interview with Reuters, Chris Lee, head of Bayer China, said the company will increase its headcount at the facility from about 135 researchers currently up to 300 in the next few years.

Charles River Labs (NYSE: CRL) intends to sell its Shanghai pre-clinical drug development lab, saying China hasnt yet developed a market for US-compliant toxicology testing (see story). The facility remains open and its owners are in talks with interested parties about purchasing the lab, according to executives close to the company. The US-based CRO owns and operates the facility through a JV that it formed with Shanghai BioExplorer.

An offshoot of the Chinese Academy of Sciences ((CAS


Complete Story

Comments

Popular posts from this blog

*What's Happening*

- Starbucks Menu Expands in China

*What's Happening*


- Kingway Parent Intervenes in

*What's Happening *

- Starbucks to take on Nestle in